Showing 1501-1510 of 2656 results for "".
- AstraZeneca’s COVID-19 Vaccine Produces Robust Immune Response in Elderlyhttps://modernod.com/news/astrazenecas-covid-19-vaccine-produces-robust-immune-response-in-elderly/2478462/AstraZeneca disclosed that its experimental COVID-19 vaccine AZD1222 triggered a robust immune response in elderly and older adults, similar to that previously seen in healthy study volunteers aged between 18 and 55. Adverse events associated with the vaccine, which is being co-developed with the
- Gilead’s Veklury Becomes First Treatment to Receive FDA Approval for COVID-19https://modernod.com/news/gileads-veklury-becomes-first-treatment-to-receive-fda-approval-for-covid-19/2478451/Gilead Sciences said Thursday that Veklury (remdesivir) has been approved by the FDA to treat hospitalized COVID-19 patients aged 12 years and older and weighing at least 40 kg, making it the first drug to gain full clearance in the US for the disease. The antiviral, which works by hindering the
- Regeneron’s Inmazeb Becomes First FDA-Approved Treatment for Ebola Virushttps://modernod.com/news/regenerons-inmazeb-becomes-first-fda-approved-treatment-for-ebola-virus/2478420/The FDA announced Wednesday that it has approved Regeneron Pharmaceuticals’ triple antibody cocktail Inmazeb (atoltivimab/maftivimab/odesivimab-ebgn) for use in adult and paediatric patients, making it the first drug cleared in the US to treat Ebola virus infection. According to the a
- Bausch Health Licenses Eyenovia’s Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12https://modernod.com/news/bausch-health-licenses-eyenovias-investigational-treatment-for-the-reduction-of-pediatric-myopia-progression-in-children-ages-3-12/2478405/Bausch Health Companies and Eyenovia announced that an affiliate of Bausch Health has acquired an exclusive license in the United States and Canada for the development and commercialization of an investigational microdose formulati
- Lilly, Incyte’s Olumiant Shows “Significant Effect” on COVID-19 Recovery Timeshttps://modernod.com/news/lilly-incytes-olumiant-shows-significant-effect-on-covid-19-recovery-times/2478401/Eli Lilly and Incyte shared more details, including mortality data, from the ongoing ACTT 2 trial evaluating their JAK1/JAK2 inhibitor Olumiant (baricitinib) in combination with Gilead Sciences’ Veklury (remdesivir) in patients with COVID-19 infection. The companies said last month that the
- AIVITA Biomedical’s Stem Cell Therapeutic in Vision Loss Published in Investigative Ophthalmology & Vision Sciencehttps://modernod.com/news/aivita-biomedicals-stem-cell-therapeutic-in-vision-loss-published-in-investigative-ophthalmology-vision-science/2478398/AIVITA Biomedical announced the publication of the peer-reviewed manuscript, “Retina organoid transplants develop photoreceptors and improve visual function in RCS rats with RPE dysfunction,” in the journal Investigative Ophthalmology & Visual Science. The
- Moderna’s mRNA-1273 COVID-19 Vaccine Generates Immune Responses in Older Adultshttps://modernod.com/news/modernas-mrna-1273-covid-19-vaccine-generates-immune-responses-in-older-adults/2478351/Moderna said data published in the NEJM showed that its mRNA-1273 vaccine candidate against COVID-19 was well tolerated and generated strong immune responses in older adults. “These interim phase 1 data suggest that mRNA-1273 … can generate neutralizing antibodies in older and elderly adult
- Early Data Show Regeneron’s Antibody Cocktail Cuts Viral Load, Eases COVID-19 Symptomshttps://modernod.com/news/early-data-show-regenerons-antibody-cocktail-cuts-viral-load-eases-covid-19-symptoms/2478347/Regeneron Pharmaceuticals said Tuesday that adding REGN-COV2 to standard-of-care reduced viral load as well as the time to symptom alleviation in non-hospitalized patients with COVID-19. The company noted that first data from an ongoing adaptive phase 1/2/3 trial of its investigational dual antib
- Inovio’s COVID-19 Vaccine Candidate INO-4800 Hit by FDA Partial Holdhttps://modernod.com/news/inovios-covid-19-vaccine-candidate-ino-4800-hit-by-fda-partial-hold/2478341/Inovio Pharmaceuticals said that the FDA placed a partial clinical hold on a planned phase 2/3 study of its COVID-19 vaccine candidate INO-4800. According to Inovio, the FDA has “additional questions” about the planned trial, including the CELLECTRA 2000 delivery device to be
- Moody’s: Hospital Financial Outlook Worse as COVID-19 Relief Funds Start to Dwindlehttps://modernod.com/news/moodys-hospital-financial-outlook-worse-as-covid-19-relief-funds-start-to-dwindle/2478308/For-profit hospitals are expected to see a financial decline over the next 12 to 18 months as federal relief funds that shored up revenue losses due to COVID-19 start to wane, a recent analysis from Moody’s said, according to a FierceHealthcare